853 related articles for article (PubMed ID: 17060545)
1. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
2. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Soriano A; Marco F; Martínez JA; Pisos E; Almela M; Dimova VP; Alamo D; Ortega M; Lopez J; Mensa J
Clin Infect Dis; 2008 Jan; 46(2):193-200. PubMed ID: 18171250
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
[TBL] [Abstract][Full Text] [Related]
5. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Lodise TP; Miller CD; Graves J; Evans A; Graffunder E; Helmecke M; Stellrecht K
J Antimicrob Chemother; 2008 Nov; 62(5):1138-41. PubMed ID: 18694905
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ahmad NM; Rojtman AD
Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
[TBL] [Abstract][Full Text] [Related]
8. [Methicillin-resistant Staphylococcus aureus bacteremia. Predictor factors for an isolate with a vancomycin minimal inhibitory concentration > or =2 mg/l].
Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
Rev Esp Quimioter; 2008 Jun; 21(2):93-8. PubMed ID: 18509768
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.
Wong-Beringer A; Joo J; Tse E; Beringer P
Int J Antimicrob Agents; 2011 Feb; 37(2):95-101. PubMed ID: 21130609
[TBL] [Abstract][Full Text] [Related]
10. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
Brown J; Brown KA; Forrest A
Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
[TBL] [Abstract][Full Text] [Related]
12. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
Kullar R; Davis SL; Levine DP; Rybak MJ
Clin Infect Dis; 2011 Apr; 52(8):975-81. PubMed ID: 21460309
[TBL] [Abstract][Full Text] [Related]
13. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
[TBL] [Abstract][Full Text] [Related]
14. Increasing incidence of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: reconsideration of empiric antimicrobial therapy.
Awad SS; Elhabash SI; Lee L; Farrow B; Berger DH
Am J Surg; 2007 Nov; 194(5):606-10. PubMed ID: 17936421
[TBL] [Abstract][Full Text] [Related]
15. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.
Yoon YK; Kim JY; Park DW; Sohn JW; Kim MJ
J Antimicrob Chemother; 2010 May; 65(5):1015-8. PubMed ID: 20200036
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.
Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Gao W; Christiansen KJ; Coombs GW; Johnson PD; Howden BP
J Infect Dis; 2011 Aug; 204(3):340-7. PubMed ID: 21742831
[TBL] [Abstract][Full Text] [Related]
17. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
18. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
19. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
20. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation.
Miller LG; Perdreau-Remington F; Bayer AS; Diep B; Tan N; Bharadwa K; Tsui J; Perlroth J; Shay A; Tagudar G; Ibebuogu U; Spellberg B
Clin Infect Dis; 2007 Feb; 44(4):471-82. PubMed ID: 17243048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
